Bone fragility is recognized as one of the major comorbidities in Turner syndrome (TS). The mechanisms underlying bone impairment in affected patients are not clearly elucidated, but estrogen deficiency and X-chromosomal abnormalities represent important factors. Moreover, although many girls with TS undergo recombinant growth hormone therapy to treat short stature, the efficacy of this treatment on bone mineral density is controversial. The present review will focus on bone fragility in subjects with TS, providing an overview on the pathogenic mechanisms and some prevention strategies.

Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies

FAIENZA, Maria Felicia;VENTURA, ANNAMARIA;COLUCCI, Silvia Concetta;CAVALLO, Luciano;GRANO, Maria;BRUNETTI, GIACOMINA
2016-01-01

Abstract

Bone fragility is recognized as one of the major comorbidities in Turner syndrome (TS). The mechanisms underlying bone impairment in affected patients are not clearly elucidated, but estrogen deficiency and X-chromosomal abnormalities represent important factors. Moreover, although many girls with TS undergo recombinant growth hormone therapy to treat short stature, the efficacy of this treatment on bone mineral density is controversial. The present review will focus on bone fragility in subjects with TS, providing an overview on the pathogenic mechanisms and some prevention strategies.
File in questo prodotto:
File Dimensione Formato  
frontiers_endocrinology.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 346.37 kB
Formato Adobe PDF
346.37 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/165940
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 31
social impact